73 trials changed in the last 30 days: 1 stopped, 22 with notable changes, 50 with minor changes only.
Trial terminated
Also in this update: Trial sites reduced: 31 → 24 locations; Primary completion date changed from estimate of Aug 2, 2028 to Sep 23, 2026
PfizerPhase 2 NCT05070845 Registry history of NCT05070845 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 28, 2026 to Oct 25, 2029
PfizerPhase 4 NCT05144997 Registry history of NCT05144997 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 31, 2026 to Mar 1, 2027
PfizerNot specified NCT07567352 Registry history of NCT07567352 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Oct 7, 2026; Trial completed
PfizerPhase 2 NCT03709680 Registry history of NCT03709680 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Sep 29, 2026
Seagen, a wholly owned subsidiary of PfizerPhase 3 NCT05132582 Registry history of NCT05132582 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Sep 30, 2026; Study completion pushed from Sep 7, 2026 to May 25, 2027
PfizerPhase 1/2 NCT06206837 Registry history of NCT06206837 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 3 → 8
PfizerPhase 1 NCT07090499 Registry history of NCT07090499 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 1330 → 674 participants
PfizerPhase 3 NCT06873945 Registry history of NCT06873945 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 1, 2026 to Sep 24, 2026
PfizerPhase 3 NCT07792954 Registry history of NCT07792954 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 29 → 34 locations; Start date changed from estimate of Sep 28, 2026 to Oct 2, 2026; and 1 more change in the last 30 days
PfizerPhase 3 NCT07794761 Registry history of NCT07794761 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 8 → 16 locations; Start date changed from estimate of Oct 1, 2026 to Sep 30, 2026
PfizerPhase 3 NCT07845500 Registry history of NCT07845500 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 6 → 15 locations
PfizerPhase 3 NCT07819097 Registry history of NCT07819097 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 2 → 8 locations
PfizerPhase 3 NCT07772921 Registry history of NCT07772921 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 1 → 22 locations
PfizerPhase 3 NCT07783425 Registry history of NCT07783425 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 3 locations; Start date changed from estimate of Sep 19, 2026 to Sep 17, 2026; and 1 more change in the last 30 days
PfizerPhase 3 NCT07823608 Registry history of NCT07823608 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 25 → 36 locations
PfizerPhase 3 NCT07794748 Registry history of NCT07794748 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Primary completion pushed from Sep 12, 2028 to Oct 21, 2028; Study completion pushed from Dec 11, 2028 to Jan 19, 2029; and 1 more change in the last 30 days
PfizerPhase 3 NCT07729462 Registry history of NCT07729462 on ClinicalTrials.gov (opens the registry)
Reclassified as terminated (was completed)
PfizerPhase 2 NCT03307980 Registry history of NCT03307980 on ClinicalTrials.gov (opens the registry)
Recruitment opened
PfizerPhase 1 NCT07731139 Registry history of NCT07731139 on ClinicalTrials.gov (opens the registry)
Final enrollment: 1 participants — under 1% of the 7500 planned
Also in this update: Primary and study completion moved earlier from Apr 20, 2027 to Nov 20, 2026; and 1 more change in the last 30 days
PfizerNot specified NCT07821216 Registry history of NCT07821216 on ClinicalTrials.gov (opens the registry)
Trial completed
PfizerPhase 3 NCT07543380 Registry history of NCT07543380 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Sep 10, 2026
PfizerPhase 1/2 NCT06125522 Registry history of NCT06125522 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
PfizerPhase 1 NCT07153159 Registry history of NCT07153159 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
PfizerNot specified NCT07779590 Registry history of NCT07779590 on ClinicalTrials.gov (opens the registry)
Trial completed
PfizerPhase 1 NCT07597928 Registry history of NCT07597928 on ClinicalTrials.gov (opens the registry)
Trial completed
PfizerPhase 1 NCT07578636 Registry history of NCT07578636 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 31, 2026 to Oct 30, 2026
PfizerNot specified NCT07177209 Registry history of NCT07177209 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 500 → 450 participants
PfizerPhase 3 NCT06807281 Registry history of NCT06807281 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 31, 2026 to Oct 31, 2026
PfizerNot specified NCT06898047 Registry history of NCT06898047 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 463 → 460 locations
PfizerPhase 3 NCT06760637 Registry history of NCT06760637 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 253 → 256 locations
PfizerPhase 3 NCT06679140 Registry history of NCT06679140 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 21 locations
PfizerPhase 3 NCT07765888 Registry history of NCT07765888 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 41 → 67 locations
PfizerPhase 3 NCT07029828 Registry history of NCT07029828 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 10 → 17 locations
And 1 more change in the last 30 days
PfizerPhase 3 NCT07768345 Registry history of NCT07768345 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 307 → 319 locations
And 1 more change in the last 30 days
PfizerPhase 3 NCT07028853 Registry history of NCT07028853 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 223 → 230 locations
And 1 more change in the last 30 days
PfizerPhase 2/3 NCT06989437 Registry history of NCT06989437 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 58 → 72 locations
And 1 more change in the last 30 days
PfizerPhase 3 NCT07595549 Registry history of NCT07595549 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 183 → 180 locations
And 1 more change in the last 30 days
PfizerPhase 3 NCT07400653 Registry history of NCT07400653 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 167 → 161 locations
PfizerPhase 3 NCT07311850 Registry history of NCT07311850 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 21 → 24 locations
And 1 more change in the last 30 days
PfizerPhase 4 NCT07609914 Registry history of NCT07609914 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 33 → 42 locations
And 1 more change in the last 30 days
PfizerPhase 2 NCT07216027 Registry history of NCT07216027 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 10 locations
PfizerPhase 1 NCT06703606 Registry history of NCT06703606 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 167 → 157 locations
PfizerPhase 1/2 NCT06966453 Registry history of NCT06966453 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 21 → 26 locations
PfizerPhase 1 NCT07426757 Registry history of NCT07426757 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 479 → 484 locations
And 1 more change in the last 30 days
PfizerPhase 3 NCT07222566 Registry history of NCT07222566 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 348 → 372 locations
And 2 more changes in the last 30 days
PfizerPhase 3 NCT07222800 Registry history of NCT07222800 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 39 → 43 locations
And 1 more change in the last 30 days
PfizerPhase 3 NCT07578649 Registry history of NCT07578649 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 10 → 12 participants
PfizerNot specified NCT06476665 Registry history of NCT06476665 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 57 → 61 locations
And 1 more change in the last 30 days
PfizerPhase 2 NCT07476287 Registry history of NCT07476287 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 90 → 104 locations
And 2 more changes in the last 30 days
PfizerPhase 1/2 NCT07227298 Registry history of NCT07227298 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 29 → 37 locations
PfizerPhase 2 NCT07489066 Registry history of NCT07489066 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 162 → 183 locations
And 3 more changes in the last 30 days
PfizerPhase 1/2 NCT07227415 Registry history of NCT07227415 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 173 → 184 locations
And 1 more change in the last 30 days
PfizerPhase 1/2 NCT07421700 Registry history of NCT07421700 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 23 → 39 locations
PfizerPhase 3 NCT05568719 Registry history of NCT05568719 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 431 → 449 locations
PfizerPhase 3 NCT07144280 Registry history of NCT07144280 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 372 → 389 locations
PfizerPhase 3 NCT06758401 Registry history of NCT06758401 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 139 → 160 locations
PfizerPhase 3 NCT05623020 Registry history of NCT05623020 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 152 → 158 locations
PfizerPhase 3 NCT07013474 Registry history of NCT07013474 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 206 → 216 locations
PfizerPhase 3 NCT07160244 Registry history of NCT07160244 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 28 locations
PfizerPhase 3 NCT07794774 Registry history of NCT07794774 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 236 → 233 locations
PfizerPhase 3 NCT06629779 Registry history of NCT06629779 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 54 → 58 locations
PfizerPhase 1/2 NCT07227012 Registry history of NCT07227012 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 2 → 6 locations
PfizerPhase 4 NCT07685769 Registry history of NCT07685769 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 26 → 30 locations
PfizerPhase 2 NCT06462235 Registry history of NCT06462235 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 132 → 137 locations
PfizerPhase 2 NCT06977581 Registry history of NCT06977581 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 15 → 20 locations
PfizerPhase 1 NCT07519655 Registry history of NCT07519655 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 0 → 7 locations
PfizerPhase 1 NCT07663630 Registry history of NCT07663630 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Jan 14, 2033 to Jul 21, 2032
Also in this update: Primary completion moved earlier from Jan 15, 2032 to Jul 22, 2031; and 3 more changes in the last 30 days
PfizerPhase 2/3 NCT07392892 Registry history of NCT07392892 on ClinicalTrials.gov (opens the registry)
Interventions modified
PfizerPhase 1 NCT03460977 Registry history of NCT03460977 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Nov 13, 2026 to Jan 31, 2027
PfizerNot specified NCT07235397 Registry history of NCT07235397 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-15 | NCT07874633 A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared… | Phase 3 | Not Yet Recruiting |
| 2026-10-15 | NCT07876518 A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are… | Phase 1 | Not Yet Recruiting |
| 2026-10-15 | NCT07876531 A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken… | Phase 1 | Not Yet Recruiting |
| 2026-10-09 | NCT07869043 A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With… | Phase 3 | Recruiting |
| 2026-10-05 | NCT07859527 A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia… | Not Yet Recruiting | |
| 2026-09-29 | NCT07845500 A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide… | Phase 3 | Recruiting |
| 2026-09-29 | NCT07845513 A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese… | Phase 1 | Not Yet Recruiting |
| 2026-09-24 | NCT07839871 Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of… | Phase 3 | Not Yet Recruiting |
| 2026-09-24 | NCT07839884 A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing… | Phase 3 | Not Yet Recruiting |
| Phase 1 | 44 | |
| Phase 1/2 | 12 | |
| Phase 2 | 32 | |
| Phase 2/3 | 5 | |
| Phase 3 | 87 | |
| Phase 4 | 9 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07685769 | A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India | Acute Treatment of Migraine | Recruiting | 2026-10-15 |
| NCT07609914 | A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant… | Acute Treatment of Migraine | Recruiting | 2026-10-14 |
| NCT06952660 | Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical… | Cervical Cancer | Recruiting | 2026-10-13 |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and… | Solid Tumors | Recruiting | 2026-10-02 |
| NCT06057402 | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | Multiple Myeloma | Recruiting | 2026-07-01 |
| NCT05144997 | Lorlatinib Continuation Study | Non-Small-Cell Lung Cancer | Active, Not Recruiting | 2026-09-23 |
| NCT07768358 | Tucatinib Continuation Study | HER2-positive Breast Cancer | Not Yet Recruiting | 2026-08-28 |
| NCT05295290 | A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are… | Myocarditis | Active, Not Recruiting | 2026-05-07 |
| NCT05160922 | Crizotinib Continuation Clinical Study | NSCLC | Active, Not Recruiting | 2026-03-30 |
| Phase 3 | ||||
| NCT06679140 | A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent… | COVID-19 SARS-CoV-2 Infection | Recruiting | 2026-10-15 |
| NCT07029828 | A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With… | Severe Alopecia Areata | Recruiting | 2026-10-15 |
| NCT07765888 | A Study to Learn About the Study Medicine Called Tilrekimig in People With… | Atopic Dermatitis | Recruiting | 2026-10-15 |
| NCT07792954 | A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared… | Obesity | Recruiting | 2026-10-15 |
| NCT07794761 | A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in… | Obesity | Recruiting | 2026-10-15 |
| NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide… | Obesity | Recruiting | 2026-10-15 |
| NCT05156398 | Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in… | Migraine | Recruiting | 2026-10-14 |
| NCT05611801 | A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A… | Hemophilia A | Recruiting | 2026-10-14 |
| NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic… | Metastatic Castration-Resistant Prostate Cancer | Recruiting | 2026-10-14 |
| NCT06866405 | A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and… | RSV Infection | Recruiting | 2026-10-14 |
| NCT07013474 | A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are… | COVID-19 Infection | Recruiting | 2026-10-14 |
| NCT07028853 | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat… | Metastatic Castration Sensitive Prostate Cancer (mCSPC) | Recruiting | 2026-10-14 |
| NCT07729462 | A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the… | Preventive Treatment of Migraine | Recruiting | 2026-10-14 |
| NCT07768345 | A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised… | Respiratory Syncytial Virus (RSV) | Recruiting | 2026-10-14 |
| NCT07794748 | A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent… | Pneumococcal Disease | Recruiting | 2026-10-14 |
| NCT06807281 | A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older… | Atopic Dermatitis | Recruiting | 2026-10-13 |
Lung Cancer (33) · Breast Cancer (30) · Non-Small Cell Lung Cancer (NSCLC) (29) · Obesity (18) · Colorectal Cancer (14) · Atopic Dermatitis (13) · Migraine (13) · Multiple Myeloma (11) · Prostate Cancer (10) · Bladder Cancer (9)